Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 200 of 373

Guidance and quality standards awaiting development
Title	Type
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]	Technology appraisal guidance
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance
Iptacopan for treating primary IgA nephropathy [ID6640]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]	Technology appraisal guidance
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]	Technology appraisal guidance
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication	HealthTech guidance
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]	Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]	Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]	Technology appraisal guidance
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Luspatercept for treating haemoglobin H disease [ID6714]	Technology appraisal guidance
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]	Technology appraisal guidance
Managing symptoms with an uncertain cause	Quality standard
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689]	Technology appraisal guidance
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]	Technology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance
Miniature lens system implantation for advanced age-related macular degeneration	HealthTech guidance
Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]	Technology appraisal guidance
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain	HealthTech guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]	Technology appraisal guidance
Obinutuzumab for treating primary membranous nephropathy [ID6751]	Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]	Technology appraisal guidance

Results per page

10
25
50
All